Technical analysis of Biodesix, Inc. (BDSX): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Biodesix, Inc. is a data-driven diagnostic solutions provider operating across the United States. Its primary focus includes a comprehensive suite of blood-based lung tests, marketed as the Nodify Lung Nodule Risk Assessment (which includes Nodify XL2 and Nodify CDT). These assessments enable clinicians to evaluate the risk of lung cancer in patients with suspicious nodules, aiding in the reclassification of malignancy risk and guiding appropriate treatment pathways.
Price Performance
| 1 month | +27.84% |
| 3 months | +69.90% |
| Year-to-date | +320.00% |
| 1 year | +359.90% |
| 3 years | -4.16% |
| 5 years | -83.62% |
52-Week Range
| 52-week High | $31.31 |
| 52-week Low | $5.26 |
| Avg Volume (90d) | 84K |
Technical Indicators
| SMA 50 | $23.95 |
| SMA 200 | $15.67 |
| Beta | 0.57 |
| 30-day Volatility (annualised) | 84.5% |
| Price vs SMA 50 | +19.3% |
| Price vs SMA 200 | +82.3% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $6.83 | |
| 2025-11 | $8.28 | +21.2% |
| 2025-12 | $6.80 | -17.9% |
| 2026-01 | $10.17 | +49.6% |
| 2026-02 | $15.33 | +50.7% |
| 2026-03 | $14.50 | -5.4% |
| 2026-04 | $10.98 | -24.3% |
| 2026-05 | $16.32 | +48.6% |
| 2026-06 | $22.55 | +38.2% |
| 2026-07 | $21.20 | -6.0% |
| 2026-08 | $26.35 | +24.3% |
| 2026-09 | $28.56 | +8.4% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | | |
| 2026-09-14 | | $563M |
| 2026-09-14 | | |
| 2026-09-14 | | $159M |
| 2026-09-14 | $0.20 | $23M |
| 2026-09-14 | | |
Price
| Price | $28.56 |
| Market Cap | $232M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 32.11 |
| EV / EBITDA | -17.85 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 7.85 |
| Current Ratio | 2.85 |
| Piotroski F-Score | 4 |
| Altman Z-Score | -7.45 |